Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Maze Therapeutics (MAZE) to $34 from $19 and keeps a Buy rating on the shares after the company announced clinical results from the Phase 1 healthy volunteer study of MZE782. The healthy volunteer urinary Phe data exceeded a 10-times threshold with the reported 24-55-times increase, indicating a potentially superior profile relative to comps, and the MZ782 data imply the medicine has the potential to beat on efficacy, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics price target raised to $50 from $34 at H.C. Wainwright
- Maze Therapeutics Advances Clinical Programs Amid Financial Stability
- Maze Therapeutics price target raised to $37 from $30 at BTIG
- Maze Therapeutics price target raised to $34 from $28 at Leerink
- Kroger reports mixed Q2, U.S. CPI rises 0.4% in August: Morning Buzz